Clinical Myocarditis: Clinical Presentation and Management

Mariell Jessup MD, FAHA, FESC, FACC Emeritus Professor, University of Pennsylvania Chief Scientific Officer, Fondation Leducq



Disclosure:

Mariell Jessup MD

University of Pennsylvania

- Speakers Bureau:
- Advisory Board:
- <u>Honorarium:</u>



STATE-OF-THE-ART PAPER


Update on Myocarditis

J Am Coll Cardiol 2012;59:779-92

Ingrid Kindermann, MD,* Christine Barth,* Felix Mahfoud, MD,* Christian Ukena, MD,* Matthias Lenski, MD,* Ali Yilmaz, MD,† Karin Klingel, MD,‡ Reinhard Kandolf, MD,‡ Udo Sechtem, MD,† Leslie T. Cooper, MD,§ Michael Böhm, MD*

In 1995, myocarditis was defined by the World Health Organization /International Society and Federation of Cardiology as an inflammatory disease of the heart muscle, diagnosed by established histological, immunological, and immunohistochemical criteria.

Etiology	Subgroups Examples
Infectious	Bacterial: Chlamydia, Corynebacterium diphtheria, Legionella, Mycobacterium tuberculosis, Mycoplasma, Staphylococcus, Streptococcus A, Streptoccocus pneumoniae
	Fungal: Actinomyces, Aspergillus, Candida, Cryptococcus
	Helminthic: Echinococcus granulosus, Trichinella spiralis
	Protozoal: Toxoplasma gondii, Trypanosoma cruzi
	Viral: Adenoviruses, Echoviruses, Enteroviruses (e.g., Coxsackieviruses), Herpes Viruses (Human Cytomegalovirus, Epstein-Barr virus, Human Herpesvirus 6), Hepatitis C Virus, Human Immunodeficiency Virus (HIV), Influenza A virus, Parvovirus B19
	Rickettsial: Coxiella burnetti, Rickettsia typhi
	Spirochetal: Borrelia burgdorferi, Leptospira, Treponema pallidum
Autoimmune diseases	Celiac disease, Churg-Strauss syndrome, Crohn's disease, dermatomyositis, giant cell myocarditis, hypereosinophilic syndrome, Kawasaki disease, lupus erythematodes, lymphofollicular myocarditis, rheumatoid arthritis, sarcoidosis, scleroderma, ulcerative colitis
Hypersensitivity reactions to drugs	Penicillin, ampicillin, cephalosporins, tetracyclines, sulfonamids, antiphlogistics, benzodiazepines, clozapine, loop and thiazide diuretics, methyldopa, smallpox vaccine, tetanus toxoid, tricyclic antidepressants
Toxic reactions to drugs	Amphetamines, anthracyclines, catecholamines, cocaine, cyclophoshamide, 5-fluorouracil, phenytoin, trastuzumab
Тохіс	Ethanol
Others	Arsenic, copper, iron, radiotherapy, thyreotoxicosis



Pathophysiology of Viral Myocarditis

Kindermann et al. J Am Coll Cardiol 2012;59:779–92

STATE-OF-THE-ART PAPER

Update on Myocarditis

J Am Coll Cardiol 2012;59:779-92


Ingrid Kindermann, MD,* Christine Barth,* Felix Mahfoud, MD,* Christian Ukena, MD,* Matthias Lenski, MD,* Ali Yilmaz, MD,† Karin Klingel, MD,‡ Reinhard Kandolf, MD,‡ Udo Sechtem, MD,† Leslie T. Cooper, MD,§ Michael Böhm, MD*

Diagnosis:

- Viral serology, EKG are non-specific
- Biomarkers helpful
- Imaging very helpful
- Role of endomyocardial biopsy (EMB): critical
- Viral PCR from EMB, immunohistochemical


• Treatment:

- UNCLEAR, but treat the heart failure.



Autosomal Recessive Cardiomyopathy Presenting as Acute Myocarditis

J Am Coll Cardiol 2017;69:1653-65



EDITORIAL COMMENT

Myocarditis

An Intersection Between Genetic and Acquired Causes of Human Cardiomyopathy

JACC VOL.69, NO.13, 2017


Kirk U. Knowlton, MD

This suggests that a combination of genetic factors that increase susceptibility to cardiomyopathy combined with acquired causes of cardiomyopathy, such as viral infection, may be an explanation for the variable penetrance and severity of dilated cardiomyopathy.

Myocarditis

Circ Res. 2016;118:496-514

Gabriel Fung, Honglin Luo, Ye Qiu, Decheng Yang, Bruce McManus



Putative role of micro-RNAs (miR) in coxsackievirus B3 (CVB3) pathogenesis

Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis

Ammirati et al. Circulation. 2017;136:529-545.

Immunosuppressive treatment was not standardized, reflecting the substantial lack of data on the treatment of lymphocytic/viral myocarditis.

We did not perform molecular analysis to search for viral genome systematically because of financial constraints and a lack of strong evidence supporting viral search in endomyocardial samples to guide therapy,

Although most patients with myocarditis have a good long-term prognosis, those with fulminant presentation are more likely to have worse LV function at follow-up.

Last, because of the diagnostic accuracy of CMR we believe that EMB is indicated in patients with NFM only if LV systolic dysfunction persists despite medical therapy or when a systemic disorder is suspected.

Clinical Myocarditis: Clinical Presentation and Management

- Symptoms:
 - Chest pain, arrhythmias, heart failure
- Diagnostic evaluation:
 - Take a good history !!!
 - Biomarkers, imaging (including cath in aged patients)
 - Biopsy
- Management:
 - Telemetry, bedrest
 - Treat heart failure with evidence based drugs



Thank you